|
1
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suay G, Garcia-Cañaveras JC, Aparisi F,
Garcia J, Juan-Vidal O and Lahoz A: Immune checkpoint inhibitors as
first-line treatment for brain metastases in stage IV NSCLC
patients without driver mutations. Cancer Lett. 606:2173172024.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou Y, Zhai W, Sun W, Han Y, Lin Z, Liu
D, Zheng Y, Luo X, Zhao Z, Feng S, et al: Safety and necessity of
omitting mediastinal lymph node dissection in cN0/N1 non-small cell
lung cancer after neoadjuvant immunotherapy. Front Immunol.
16:15876582025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao L, Li M, Shen C and Luo Y, Hou X, Qi
Y, Huang Z, Li W, Gao L, Wu M and Luo Y: Nano-assisted radiotherapy
strategies: New opportunities for treatment of non-small cell lung
cancer. Research (Wash D C). 7:04292024.PubMed/NCBI
|
|
6
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016.PubMed/NCBI
|
|
7
|
Ashrafizadeh M, Zarrabi A, Hushmandi K,
Hashemi F, Moghadam ER, Owrang M, Hashemi F, Makvandi P, Goharrizi
MASB, Najafi M and Khan H: Lung cancer cells and their
sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs
and upstream mediators. Cell Signal. 78:1098712021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Du J, Wang X, Li Y, Ren X, Zhou Y, Hu W,
Zhou C, Jing Q, Yang C, Wang L, et al: DHA exhibits synergistic
therapeutic efficacy with cisplatin to induce ferroptosis in
pancreatic ductal adenocarcinoma via modulation of iron metabolism.
Cell Death Dis. 12:7052021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Srinivas US, Tan BWQ, Vellayappan BA and
Jeyasekharan AD: ROS and the DNA damage response in cancer. Redox
Biol. 25:1010842019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carusillo A and Mussolino C: DNA damage:
From threat to treatment. Cells. 9:16652020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li L, Kumar AK, Hu Z and Guo Z: Small
molecule inhibitors targeting key proteins in the DNA damage
response for cancer therapy. Curr Med Chem. 28:963–985. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu XY, Hou PF, Li TT, Quan HY, Li ML, Lin
T, Liu JJ, Bai J and Zheng JN: The roles of Wnt/β-catenin signaling
pathway related lncRNAs in cancer. Int J Biol Sci. 14:2003–2011.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xin R, Hu B, Qu D and Chen D: Oncogenic
lncRNA MALAT-1 recruits E2F1 to upregulate RAD51 expression and
thus promotes cell autophagy and tumor growth in non-small cell
lung cancer. Pulm Pharmacol Ther. 20:1021992023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma J, Setton J, Lee NY, Riaz N and Powell
SN: The therapeutic significance of mutational signatures from DNA
repair deficiency in cancer. Nat Commun. 9:32922018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roos WP, Thomas AD and Kaina B: DNA damage
and the balance between survival and death in cancer biology. Nat
Rev Cancer. 16:20–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gong T, Cui L, Wang H, Wang H and Han N:
Knockdown of KLF5 suppresses hypoxia-induced resistance to
cisplatin in NSCLC cells by regulating HIF-1alpha-dependent
glycolysis through inactivation of the PI3K/Akt/mTOR pathway. J
Transl Med. 16:1642018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu S, Yang Z, Jin P, Yang X, Li X, Wei X,
Wang Y, Long S, Zhang T, Chen G, et al: Metformin suppresses tumor
progression by inactivating stromal fibroblasts in ovarian cancer.
Mol Cancer Ther. 17:1291–1302. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang N, Sun X, Li P, Liu X, Zhang X, Chen
Q and Xin H: TRIM family contribute to tumorigenesis, cancer
development, and drug resistance. Exp Hematol Oncol. 11:752022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang M, Wang L, Sun Z, Chen X, Wang H,
Qin L, Zhao W and Geng B: E3 ligase TRIM15 facilitates non-small
cell lung cancer progression through mediating Keap1-Nrf2 signaling
pathway. Cell Commun Signal. 20:622022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Groner AC, Cato L, de Tribolet-Hardy J,
Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato ACB,
Tschopp P, Gu L, et al: TRIM24 is an oncogenic transcriptional
activator in prostate cancer. Cancer Cell. 29:846–858. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang L, Li X, Dong W, Sun C, Guo D and
Zhang L: Mmu-miR-1894-3p inhibits cell proliferation and migration
of breast cancer cells by targeting Trim46. Int J Mol Sci.
17:6092016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang W, Cai X, Xu T, Liu K, Yang D, Fan
L, Li G and Yu X: Tripartite Motif-containing 46 promotes viability
and inhibits apoptosis of osteosarcoma cells by activating NF-B
signaling through ubiquitination of PPAR. Oncol Res. 28:409–421.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tantai J, Pan X, Chen Y, Shen Y and Ji C:
TRIM46 activates AKT/HK2 signaling by modifying PHLPP2
ubiquitylation to promote glycolysis and chemoresistance of lung
cancer cells. Cell Death Dis. 13:2852022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He S, Ma X, Zheng N, Wang G, Wang M, Xia W
and Yu D: PRDM14 mediates chemosensitivity and glycolysis in
drug-resistant A549/cisplatin cells and their progenitor A549 human
lung adenocarcinoma cells. Mol Med Rep. 23:1492021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen CC, Chen CY, Ueng SH, Hsueh C, Yeh
CT, Ho JY, Chou LF and Wang TH: Corylin increases the sensitivity
of hepatocellular carcinoma cells to chemotherapy through long
noncoding RNA RAD51-AS1-mediated inhibition of DNA repair. Cell
Death Dis. 9:5432018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen SH and Chang JY: New insights into
mechanisms of cisplatin resistance: From tumor cell to
microenvironment. Int J Mol Sci. 20:41362019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Romani AMP: Cisplatin in cancer treatment.
Biochem Pharmacol. 206:1153232022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sancho-Martinez SM, Prieto-Garcia L,
Prieto M, López-Novoa JM and López-Hernández FJ: Subcellular
targets of cisplatin cytotoxicity: An integrated view. Pharmacol
Ther. 136:35–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Zhang C, Wang X, Hu W and Feng Z:
Tumor suppressor p53 cross-talks with TRIM family proteins. Genes
Dis. 8:463–474. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhan W and Zhang S: TRIM proteins in lung
cancer: Mechanisms, biomarkers and therapeutic targets. Life Sci.
268:1189852021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan L, Zhang D, Shao Q, Cheng M, Liao Z,
Yu L, Wang Y, Jia P and Zhang J: Panax notoginseng improves the
sensitivity of non-small cell lung cancer to cisplatin by
inhibiting Akt signaling. Cancer Biomark. 42:187585922413033772025.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhong Y, Luo B, Hong M, Hu S, Zou D, Yang
Y, Wei S, Faruque MO, Dong S, Zhu X, et al: Oxymatrine induces
apoptosis in non-small cell lung cancer cells by downregulating
TRIM46. Toxicon. 244:1077732024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu S, Xiao C, Rong Y, Liu M, Yang K, Tang
J and Wang Z: Comprehensive analysis of ferroptosis-related genes
indicates that TRIM46 is a novel biomarker and promotes the
progression of ovarian cancer via modulating ferroptosis and Wnt
signaling pathway. Am J Cancer Res. 14:4686–4707. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu L, Wan X, Shan X, Zha W, Shi Y and Fan
R: ONECUT3 activates the TRIM46-NF-κB pathway to promote the
development of pancreatic cancer. Biochem Biophys Res Commun.
759:1517052025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhan W, Han T, Zhang C, Xie C, Gan M, Deng
K, Fu M and Wang JB: TRIM59 promotes the proliferation and
migration of non-small cell lung cancer cells by upregulating cell
cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z,
Li W, Hu J, Lu C and Liu Y: PI3K/AKT pathway as a key link
modulates the multidrug resistance of cancers. Cell Death Dis.
11:7972020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JH, Liu R, Li J, Wang Y, Tan L, Li XJ,
Qian X, Zhang C, Xia Y, Xu D, et al: EGFR-phosphorylated platelet
isoform of phosphofructokinase 1 promotes PI3K activation. Mol
Cell. 70:197–210.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ke B, Wei T, Huang Y, Gong Y, Wu G, Liu J,
Chen X and Shi L: Interleukin-7 Resensitizes Non-small-cell lung
cancer to cisplatin via inhibition of ABCG2. Mediators Inflamm.
2019:72414182019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang L, Li J, Lv X, Guo T, Li W and Zhang
J: MID1-PP2A complex functions as new insights in human lung
adenocarcinoma. J Cancer Res Clin Oncol. 144:855–864. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Peng L, Liu L, Xu L, Chen J, Wang X, Zhang
M and Ge Y: TRIM46 promotes chemoresistance of ovarian cancer via
activating PHLPP2/PI3K/AKT pathway. Biochem Cell Biol. 103:1–9.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xie H, Yao J, Wang Y and Ni B:
Exosome-transmitted circVMP1 facilitates the progression and
cisplatin resistance of non-small cell lung cancer by targeting
miR-524-5p-METTL3/SOX2 axis. Drug Deliv. 29:1257–1271. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He R and Liu H: TRIM59 knockdown blocks
cisplatin resistance in A549/DDP cells through regulating
PTEN/AKT/HK2. Gene. 747:1445532020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pan X, Chen Y, Shen Y and Tantai J:
Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in
A549/DDP cells by regulating miR-138-5p/ATG7. Cell Death Dis.
10:4292019. View Article : Google Scholar : PubMed/NCBI
|
